Risk factors for interstitial lung disease induced by gemcitabine plus albumin-bound paclitaxel therapy in pancreatic ductal adenocarcinoma patients

BACKGROUND: Gemcitabine plus nab-paclitaxel (GnP) therapy is used for unresectable pancreatic ductal adenocarcinoma, but may cause interstitial lung disease (ILD) as a serious side effect. However, the risk factors for ILD in patients receiving GnP therapy are not well established. Here, we retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Rikako, Yamamoto, Naho, Hori, Yuki, Yoshida, Kouji, Ohtsubo, Koushiro, Terashima, Takeshi, Shimada, Tsutomu, Sai, Yoshimichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809002/
https://www.ncbi.nlm.nih.gov/pubmed/35105386
http://dx.doi.org/10.1186/s40780-021-00236-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809002/
https://www.ncbi.nlm.nih.gov/pubmed/35105386
http://dx.doi.org/10.1186/s40780-021-00236-5

Ejemplares similares